高盛上调百济神州ADR及A股目标价,看好其在慢性淋巴细胞白血病治疗领域的领导地位及BTK/BCL2产品组合潜力,预测其2035年销售额将高达88亿美元。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.